Boldenone 200 mg/mL (Prime)

1. Description

Boldenone 200 mg/mL (Prime) is an oil-based intramuscular injectable formulation whose active steroid is boldenone (commonly supplied as the undecylenate ester). Boldenone is an anabolic–androgenic steroid (AAS) developed originally for veterinary use (notably in horses and cattle) to promote weight gain, improve appetite and muscle mass. It is not an approved anabolic therapy for routine human medical indications in many jurisdictions and is a prohibited substance in competitive sport (WADA).

Pharmaceutical formulation characteristics typically include:

• Active compound: boldenone (undecylenate ester) 200 mg per mL in an oil vehicle.
• Intended route: intramuscular injection (deep IM depot).
• Long-acting depot formulation: the undecylenate ester prolongs release and activity.

Because regulatory status varies by country, clinical use in humans should only occur under licensed medical supervision where indicated and lawful.

2. How does Boldenone 200 mg/mL (Prime) work?

Mechanism of action (concise, medical):

• Boldenone is an androgen receptor (AR) agonist. It binds to ARs in target tissues (muscle, bone, bone marrow, etc.), triggering transcriptional programs that increase protein synthesis and decrease protein breakdown, producing anabolic effects (increased lean tissue).
• It increases nitrogen retention and stimulates erythropoiesis (red blood cell production) via effects on bone marrow.
• Boldenone can be aromatized to estrogenic metabolites, though its aromatization rate is lower than testosterone; therefore estrogenic effects (water retention, gynecomastia) are possible but generally less pronounced.
• Like other AAS, boldenone exerts negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis, suppressing endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release and reducing endogenous testosterone production.
• Depot ester (undecylenate) prolongs systemic exposure; pharmacokinetic parameters depend on the ester, oil vehicle, and injection site.

Clinical consequences of mechanism:

• Anabolic: increased muscle mass, strength, appetite.
• Androgenic: virilization (especially relevant in females), acne, body hair changes.
• Hematologic: increased hematocrit/hemoglobin, which can increase thrombotic risk if excessive.
• Endocrine suppression: risk of hypogonadism and infertility after use cessation.

3. Dosage

Important safety note up front: Boldenone (undecylenate) is primarily a veterinary product and is not an approved standard therapy for humans in many countries. There is no universally accepted, evidence-based human dosing regimen approved by regulatory authorities. Use in humans should only occur under the guidance of a licensed clinician where lawful, and after a thorough risk–benefit assessment.

Medical/veterinary dosing (general guidance—follow product label and veterinarian direction):

• Veterinary indications and dosing vary by species and product. For equine use, product information commonly describes intramuscular depot injections given at intervals of several weeks; reported dosing ranges in veterinary references are typically on the order of 1–3 mg/kg per injection, with intervals determined by the product label and the treating veterinarian.
• For food-producing animals, withdrawal times and legal constraints must be strictly observed; many jurisdictions prohibit use in animals intended for human consumption.

Human usage information and caution (educational):

• Boldenone is not approved for routine human therapeutic use; therefore there is no sanctioned human dosing recommendation. Use by athletes/bodybuilders outside medical supervision is associated with significant health risks and legal issues (controlled-substance laws, anti-doping rules).
• If a clinician elects to use androgen therapy for an approved indication, licensed testosterone formulations and regulated androgen replacement protocols should be used rather than veterinary boldenone formulations.

Monitoring during any medically supervised use:

• Baseline and periodic assessment: blood pressure, CBC (hematocrit/hemoglobin), fasting lipid profile, liver tests (ALT/AST, though injectable non-17α-alkylated AAS are less hepatotoxic than oral alkylated steroids), serum total testosterone, LH/FSH, estradiol, and PSA in men (age-appropriate).
• Dosing adjustments and discontinuation decisions should be made by a treating physician based on clinical response and laboratory results.

Because of legal, safety and efficacy issues, avoid unsupervised use and heed local regulation.

4. Side effects

Common and expected adverse effects

• Androgenic effects: acne, oily skin, increased facial/body hair, male-pattern baldness (in genetically susceptible men).
• Virilization in females: deepening of the voice (may be irreversible), clitoral enlargement, menstrual irregularities, hirsutism.
• Endocrine suppression: decreased endogenous testosterone production, testicular atrophy, reduced sperm production and fertility.
• Hematologic: increased hematocrit/hemoglobin (polycythemia) which raises risk of thrombosis, stroke or myocardial infarction if severe.
• Cardiovascular/metabolic: adverse changes in lipid profile (↓ HDL, ↑ LDL), possible hypertension; long-term AAS use is associated with increased cardiovascular risk.
• Local injection-site reactions: pain, swelling, inflammation, abscess formation if sterile technique is compromised.
• Emotional/behavioral: mood changes, irritability, aggression, depression on withdrawal.
• Estrogenic effects: gynecomastia and fluid retention are possible due to aromatization (less than with testosterone but still a risk).

Less common and serious/rare adverse effects

• Prostate effects in men: exacerbation of benign prostatic hyperplasia or stimulation of occult prostate cancer.
• Hepatic effects: injectable ester compounds are less hepatotoxic than 17-alkylated oral AAS, but abnormal liver function tests and rare hepatotoxic events have been reported in AAS users.
• Thromboembolic events: rare but serious (stroke, deep vein thrombosis, pulmonary embolism), particularly when hematocrit becomes elevated or with other risk factors.
• Persistent endocrine dysfunction: prolonged suppression of the HPG axis with risk of long-term hypogonadism after stopping AAS.
• Allergic reactions: rare hypersensitivity to excipients.
• Reproductive effects in males: impaired spermatogenesis and potential infertility; recovery may be slow or incomplete in some cases.

Contraindications and populations at high risk

• Pregnancy and breastfeeding (virilization of female fetus/infant).
• Known or suspected prostate cancer or male breast cancer.
• Significant cardiovascular disease, uncontrolled hypertension, severe hepatic or renal disease.
• Adolescents — may accelerate epiphyseal closure and impair growth.

Emergency actions for severe adverse events

• Thrombotic signs (sudden chest pain, shortness of breath, unilateral limb swelling), acute neurological deficits, severe hepatic symptoms (jaundice, severe abdominal pain) — seek immediate medical attention.
• For acute allergic or anaphylactic reactions — emergency services and standard acute management.

5. Storage

General pharmaceutical storage recommendations for an oil-based intramuscular preparation:

• Store at controlled room temperature as specified by the product label (commonly 20–25 °C / 68–77 °F). Brief excursions outside this range are sometimes acceptable per manufacturer instructions—refer to the product leaflet.
• Protect from excessive heat and direct sunlight. Do not freeze.
• Keep the container tightly closed when not in use.
• Inspect before use: do not use if solution is discolored, cloudy (if not indicated), or contains particulate matter; do not use if the vial or stopper is damaged.
• Keep out of reach of children and pets.
• Follow local regulations and product label for disposal of unused or expired medication and sharps (used needles/syringes).

Additional practical and legal notes

• Only use under prescription or veterinary order where lawful. Injection supplies and administration should be performed by trained personnel or under instruction from a healthcare professional to minimize infection and injury risks.
• Boldenone and many AAS are controlled substances in many jurisdictions; possession or distribution without appropriate prescription/authority can have legal consequences.
• For athletes: boldenone and its metabolites are detectable in urine and blood and are banned by most sports organizations.

If you need references for veterinary product labeling, clinical reviews of boldenone, or guidance on monitoring labs and managing adverse effects in a medical context, I can provide citations and further reading.